Our overall meeting this year promises to provide a better understanding of current critical issues which are inherent in macular diseases and their treatments. They include new concepts and chorioretinal imaging, the emergence of past and newly approved pharmacotherapeutic therapies, and treatment modalities, such as laser photocoagulation and photodynamic therapy for diseases associated with severe vision loss.
Other aspects in the management of these and other diseases will include nutritional supplements, epidemiological risk factors, genetic markers, possibilities for cellular transplantation, and newly recognized clinical diseases and their variants. As in the past, the organizational committee for these meetings will be represented by the medical school ophthalmological departments in the Greater New York area, in short a regionally based and sponsored academic program.
(An excerpt from the Macula 2016 program)